| Abstract: |
This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD. |
| Inventor: |
Whalley, Benjamin (London, GB); Stephens, Gary (London, GB); Williams, Claire (London, GB); Guy, Geoffrey (London, GB); Wright, Stephen (London, GB); Kikuchi, Tetsuro (London, GB) |
| Applicant: |
GW Pharma Limited (Cambridge, GB) |
| Face Assignee: |
N/A |
| Filed: |
2018-10-02 |
| Issued: |
2019-08-15 |
| Claims: |
6 |
|
US20190247324
|
11. A method of treating complex partial seizure that remains localized comprising administering cannabidiol (CBD) to a patient, wherein the CBD is present in an amount which provides a daily dose of at least 400 mg, and the CBD is present as a pure or isolated cannabinoid.
(2)
(0)
|
|
